Cytosorbents (CTSO) Competitors

Cytosorbents has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Cytosorbents has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

In the previous week, TELA Bio had 8 more articles in the media than Cytosorbents. MarketBeat recorded 9 mentions for TELA Bio and 1 mentions for Cytosorbents. TELA Bio's average media sentiment score of 0.48 beat Cytosorbents' score of 0.00 indicating that TELA Bio is being referred to more favorably in the news media.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 1.1% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytosorbents has a net margin of -48.94% compared to TELA Bio's net margin of -51.53%. Cytosorbents' return on equity of -431.65% beat TELA Bio's return on equity.

Cytosorbents presently has a consensus price target of $107.50, suggesting a potential upside of 2,736.41%. TELA Bio has a consensus price target of $2.14, suggesting a potential upside of 93.05%. Given Cytosorbents' higher possible upside, equities analysts plainly believe Cytosorbents is more favorable than TELA Bio.

Cytosorbents has a net margin of -48.94% compared to Sensus Healthcare's net margin of -88.45%. Sensus Healthcare's return on equity of -21.57% beat Cytosorbents' return on equity.

Sensus Healthcare has lower revenue, but higher earnings than Cytosorbents. Sensus Healthcare is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

In the previous week, Sensus Healthcare had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Sensus Healthcare and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.00 equaled Sensus Healthcare'saverage media sentiment score.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 10.2% of Sensus Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cytosorbents has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Sensus Healthcare has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Cytosorbents currently has a consensus price target of $107.50, suggesting a potential upside of 2,736.41%. Sensus Healthcare has a consensus price target of $5.83, suggesting a potential upside of 97.74%. Given Cytosorbents' higher probable upside, research analysts clearly believe Cytosorbents is more favorable than Sensus Healthcare.

Cytosorbents has a net margin of -48.94% compared to Nano-X Imaging's net margin of -926.05%. Nano-X Imaging's return on equity of -116.93% beat Cytosorbents' return on equity.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 7.7% of Nano-X Imaging shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cytosorbents has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

In the previous week, Cytosorbents and Cytosorbents both had 1 articles in the media. Cytosorbents' average media sentiment score of 0.00 equaled Nano-X Imaging'saverage media sentiment score.

Cytosorbents has higher revenue and earnings than Nano-X Imaging. Cytosorbents is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Cytosorbents presently has a consensus target price of $107.50, suggesting a potential upside of 2,736.41%. Nano-X Imaging has a consensus target price of $4.33, suggesting a potential upside of 705.75%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Nano-X Imaging.

Cytosorbents currently has a consensus target price of $107.50, suggesting a potential upside of 2,736.41%. Sanuwave Health has a consensus target price of $47.00, suggesting a potential upside of 736.30%. Given Cytosorbents' stronger consensus rating and higher probable upside, analysts clearly believe Cytosorbents is more favorable than Sanuwave Health.

In the previous week, Sanuwave Health had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Sanuwave Health and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.00 equaled Sanuwave Health'saverage media sentiment score.

Sanuwave Health has a net margin of 32.38% compared to Cytosorbents' net margin of -48.94%. Sanuwave Health's return on equity of 1,728.10% beat Cytosorbents' return on equity.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 42.5% of Sanuwave Health shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 14.4% of Sanuwave Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cytosorbents has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Sanuwave Health has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Sanuwave Health has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.